Table 1.
Patient demographics and biochemical parameters on four sampling occasions after renal transplantation (median (range))
| Characteristics | Missing data | Days 0–4 | Month 1 | Month 6 | Year 1 |
|---|---|---|---|---|---|
| Gender (n) | |||||
| Male | 0% | 157 | 119 | 87 | 104 |
| Female | 0% | 89 | 69 | 47 | 67 |
| Race (n) | |||||
| Caucasian | 0% | 217 | 168 | 121 | 131 |
| Black | 0% | 17 | 7 | 4 | 37 |
| Other | 0% | 12 | 13 | 9 | 3 |
| Diabetes mellitus (n) | 0% | 49 | 17 | 15 | 16 |
| DGF (n) | 3.8% | 34 | – | – | – |
| Use of antacids (n) | 0% | 56 | 24 | 0 | 1 |
| Use of proton pump inhibitors (n) | 0% | 7 | 13 | 0 | 0 |
| Use of H2-receptor antagonists (n) | 0% | 66 | 82 | 3 | 5 |
| Use of antiviral agents (n) | 0% | 68 | 8 | 1 | 0 |
| Use of sirolimus (n) | 20% | 21 | 27 | 17 | 2 |
| Age (years) | 0% | 50 (18–72) | 50 (19–70) | 49 (28–70) | 52 (22–73) |
| Body weight (kg) | 0.1% | 71 (37–151) | 68 (38–151) | 80 (42–151) | 75 (49–122) |
| Serum creatinine (µmol l−1) | 2.9% | 424 (66–1379) | 128 (53–913) | 124 (62–195) | 125 (52–221) |
| Creatinine clearance (ml min−1) | 2.9% | 19 (4–132) | 55 (7–203) | 71 (44–132) | 64 (34–113) |
| Plasma albumin (g l−1) | 14% | 35 (23–51) | 35 (26–50) | 36 (29–45) | 42 (31–48) |
| Serum ALT (U l−1) | 12% | 17 (2–653) | 17 (4–144) | 25 (10–128) | 20 (11–1759) |
| Serum total bilirubin (mg dl−1) | 12% | 0.5 (0.2–3.0) | 0.6 (0.1–1.9) | 0.5 (0.1–1.6) | 0.7 (0.2–3.3) |
| Serum alkaline phosphatase (U l−1) | 12% | 64 (17–870) | 86 (25–221) | 99 (46–218) | 171 (41–347) |
| Red blood cell count (×1012 l−1) | 20% | 3.2 (1.5–4.8) | 3.4 (2.1–4.9) | 4.3 (3.5–5.9) | 4.4 (3.7–9.5) |
| Haemoglobin (g dl−1) | 3.5% | 9.7 (4.9–17) | 11 (6.7–15) | 12 (9.6–18) | 13 (7.8–18) |
| Prednisone daily dose (mg) | 11% | 30 (20–1365) | 19 (7.5–35) | 10 (0–10) | 9.4 (0–10) |
| Cyclosporin daily dose (mg) | 4.8% | 530 (0–1000) | 350 (0–1400) | 100 (0–200) | 138 (0–300) |
| Cyclosporin predose concentration (ng ml−1) | 5.3% | 171 (0–806) | 237 (0–571) | 93 (0–316) | 155 (0–1337) |
| Patients not using cyclosporin (n) | 4.8% | 102 | 27 | 17 | 34 |
| Mycophenolate mofetil dose (mg twice daily) | 0% | 1150 (400–2200) | 1000 (250–2200) | 1000 (1000–1000) | 1000 (250–1250) |
Data were collected from 468 renal transplant recipients participating in six clinical studies. Because of different sampling times after transplantation in the studies, the number of individuals from whom data were available differs for the four presented occasions. n = number of renal transplant recipients, DGF = delayed graft function. Normal values as used at Erasmus MC, Rotterdam, the Netherlands for creatinine: 65–115 mol l−1 for males and 55–90 mol l−1 for females, for plasma albumin: 35–50 g l−1, for serum ALT: < 41 U l−1 for males and < 31 U l−1 for females, for serum total bilirubin: < 1 mg dl−1, for serum alkaline phosphatase: < 120 U l−1, for red blood cell count: 4.4–5.6×1012l−1 for males and 3.9–4.9 × 1012l−1 for females, for haemoglobin: 13.8–16.9 g dl−1 for males and 12.1–15.3 mg dl−1 for females.